CN112546085A - 一种治疗痛风的接骨草提取物及其制备方法 - Google Patents
一种治疗痛风的接骨草提取物及其制备方法 Download PDFInfo
- Publication number
- CN112546085A CN112546085A CN202011452388.0A CN202011452388A CN112546085A CN 112546085 A CN112546085 A CN 112546085A CN 202011452388 A CN202011452388 A CN 202011452388A CN 112546085 A CN112546085 A CN 112546085A
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- sambucus chinensis
- gout
- extracting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 119
- 201000005569 Gout Diseases 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 240000006322 Sambucus chinensis Species 0.000 title claims abstract description 37
- 235000010426 Sambucus chinensis Nutrition 0.000 title claims abstract description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 114
- 244000190529 Cynoglossum amabile Species 0.000 claims abstract description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 47
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 29
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940116269 uric acid Drugs 0.000 claims abstract description 25
- 238000010438 heat treatment Methods 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 238000010828 elution Methods 0.000 claims abstract description 14
- 230000001105 regulatory effect Effects 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 12
- 238000010298 pulverizing process Methods 0.000 claims abstract description 8
- 238000000926 separation method Methods 0.000 claims abstract description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000004440 column chromatography Methods 0.000 claims abstract description 7
- 239000000741 silica gel Substances 0.000 claims abstract description 7
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 7
- 241000208829 Sambucus Species 0.000 claims abstract description 6
- 235000008995 european elder Nutrition 0.000 claims abstract description 6
- 241000208828 Caprifoliaceae Species 0.000 claims abstract description 3
- 239000000706 filtrate Substances 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 19
- 239000012153 distilled water Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 241000220436 Abrus Species 0.000 claims description 12
- 241001519271 Ajuga Species 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 32
- 229940079593 drug Drugs 0.000 abstract description 13
- 239000006286 aqueous extract Substances 0.000 abstract description 10
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 235000018735 Sambucus canadensis Nutrition 0.000 abstract description 2
- 235000007123 blue elder Nutrition 0.000 abstract description 2
- 235000007124 elderberry Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- 230000008961 swelling Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 201000001431 Hyperuricemia Diseases 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 241001533451 Ajuga ciliata Species 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 5
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 5
- 229940074393 chlorogenic acid Drugs 0.000 description 5
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 5
- 235000001368 chlorogenic acid Nutrition 0.000 description 5
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241001519274 Ajuga reptans Species 0.000 description 4
- 206010018634 Gouty Arthritis Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 4
- 229960003459 allopurinol Drugs 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001643425 Tinospora sinensis Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960002708 antigout preparations Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 244000135727 Abrus pulchellus subsp cantoniensis Species 0.000 description 2
- 235000017112 Abrus pulchellus subsp cantoniensis Nutrition 0.000 description 2
- 241000227129 Aconitum Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000218176 Corydalis Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000605422 Asparagus asparagoides Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241001252601 Blumea Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 240000008918 Chaenomeles cathayensis Species 0.000 description 1
- 235000009810 Chaenomeles cathayensis Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 241001523681 Dendrobium Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 244000286838 Eclipta prostrata Species 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 241001646826 Isodon rubescens Species 0.000 description 1
- 241000207984 Justicia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 240000005746 Ruta graveolens Species 0.000 description 1
- 235000001347 Ruta graveolens Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 244000261559 Smilax china Species 0.000 description 1
- 235000000485 Smilax china Nutrition 0.000 description 1
- 241001063882 Smilax moranensis Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 240000001519 Verbena officinalis Species 0.000 description 1
- 235000018718 Verbena officinalis Nutrition 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 229940084627 colchicine 0.5 mg Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 239000001229 ruta graveolens Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗痛风的接骨草提取物及其制备方法,接骨草为忍冬科接骨木属接骨草的全草,接骨草提取物为接骨草水提物的乙醇洗脱部位,提取方法为:取接骨草粉碎成细粉,加入适量水加热提取2~4次,收集提取液浓缩至1.0~1.2g/m;再采用硅胶色谱柱对以上浓缩液进行柱层析分离,以不同浓度乙醇为流动相进行梯度洗脱,收集各洗脱物浓缩至浸膏。本发明的接骨草提取物制备方法简单,成本低,得到的接骨草提取物在制备治疗/预防痛风及其相关疾病或具有调节尿酸功能药物方面应用药物疗效好,成药经济效益高。
Description
技术领域
本发明属于中医药技术领域,具体涉及一种治疗痛风的接骨草提取物及其制备方法。
背景技术
痛风(gout)是一种由于嘌呤代谢紊乱产生过多尿酸及(或)尿酸排泄减少致尿酸水平升高,并形成尿酸结晶沉积于关节、软组织、肾脏等引发的一组代谢性疾病。尿酸是人类嘌呤化合物的终末代谢产物,嘌呤代谢紊乱导致高尿酸血症(HUA)。高尿酸血症通常被认为是痛风的标志,据统计约有5~12%的高尿酸血症患者最终可发展为痛风。高尿酸血症是指在正常嘌呤饮食状态下,非同日两次空腹血尿酸水平男性高于420μmol/L,女性高于360μmol/L,即称为高尿酸血症。目前,临床上常用治疗痛风的化学药物效果明显,如秋水仙碱和别嘌呤醇,但秋水仙碱会引起腹痛、食欲不振、腹泻、恶心等症状,严重的还会引起贫血、导致肝肾功能衰竭;别嘌呤醇会引起过敏、肝肾损伤及骨髓抑制等不良反应,在一定程度上限制了其临床应用。因此,研究高效低毒的抗痛风药物已经迫在眉睫。
近几年研究发现,中药对治疗痛风也有较好的效果,并显示较小或无的毒副作用。如:专利申请CN106581091A公开了赤苍藤提取物在作为治疗痛风药物的用途。专利CN104771442B公开了对宽筋藤采用多次水提,再用乙醇洗脱的方法得到的宽筋藤提取物可用于多种目的,从食品、保健品用途到特殊疾病的药物制备用途,使其在预防或治疗高尿酸血症及其导致的痛风方面的临床应用具备科学依据。专利申请CN102836361A公开了小叶菝葜和三脉菝葜的水提物或醇提物不但能缓解急性期关节红肿热痛的炎症反应,而且能够针对病机降低血中尿酸水平,对于痛风标本兼治,可以用来制备疗效好,安全可靠的治疗急性痛风性关节炎的药物。专利CN101953842B公开了从刺五加等植物中提取分离得到丁香苷对尿酸盐致人血管内皮细胞损伤的急性痛风模型具有保护作用,并抑制ICAM-1表达,可用于制备治疗急性痛风炎症药物。专利CN101757459A公开了以党参、桂枝、川芎、没药、苍术、茯苓、天麻、白芷、延胡索、木香共十味中药材为原料,经过常规提取方法加工而成的胶囊剂,具有清热利湿、通络止痛的功效,用于防治痛风病急性发作。可见,蛮多中药材的提取物或中药复方制剂都具有制备治疗痛风药物的成药潜力,而且,中药具有副作用小、综合治疗能力强等优点,因此,开发中药材提取物的新用途,积极探索新的治疗痛风药物的潜在药物靶标,寻找新型的治疗痛风药物是当今临床亟需解决的重要问题。
接骨草是忍冬科接骨木属接骨草Sambucus chinensis Lindl.的全草,别名陆英、臭草、八棱麻、走马风、公道老、马鞭梢、秧心草等,系忍冬科接骨木属植物;全草含黄酮类、酸性成分、鞣质、糖类、核苷类、绿原酸。接骨草的根、茎、叶、花及果实均可入药,味甘、苦,性平,归肝经,具有祛风利湿、活血散瘀、消炎止痛、镇痉消肿之功效,临床上用于黄疸型肝炎、病毒性肝炎的治疗,疗效确切。
现有关于接骨草的研究主要集中在药材种植、化学成分分析、活性成分提取、用于抗肝炎、活血化瘀、接骨、抗菌消炎等方面。易继凌以接骨草的绿原酸(chlorogenic acid ,CGA)为研究对象,研究其对体外培养的成骨细胞活性的影响,研究结果发现CGA 具有调控成骨细胞增殖和分化的能力,对成骨细胞前体的分化具有一定的抑制作用,但它能通过促进骨基质的形成和骨成熟分化而促进新骨成熟(易继凌.绿原酸对体外培养成骨细胞活性影响的初步研究[D],2013-中南民族大学:生物化学与分子生物学)。黄国文等以碱溶酸沉法研究接骨草总黄酮的提取条件和抑菌作用,结果表明,提取接骨草总黄酮的最优条件是料液比1∶40 (g/mL)、温度为80℃、时间为45 min、提取液pH10;调节总黄酮提取液pH3.5沉淀接骨草总黄酮的量较多;接骨草总黄酮在酸性pH4~5时对金黄色葡萄球菌、枯草芽孢杆菌和大肠杆菌的抑制作用较强,并能够增加三种细菌的电导率,对三种菌最小抑菌浓度分别为0.63、1.25、2.50 mg/mL(黄国文,管天球,赵雨云,等.接骨草总黄酮提取工艺及其抑菌作用的研究[J],《食品工业科技》2017年13期)。朱少璇等采用了小鼠急性CCl4肝损伤模型,对陆英不同提取工艺所得的提取物进行保肝降酶药效学筛选,并把筛选出的最佳工艺提取物用不同溶剂萃取法和大孔吸附树脂分离法对活性部位进行了探索。得出结论:75%乙醇为陆英的优选提取溶剂,陆英75%乙醇提取物若经不同极性溶剂萃取,活性部位为乙酸乙酯萃取部分;若经大孔树脂纯化,则活性有效部分主要集中在30%乙醇洗脱液部分(朱少璇,廖琼峰,王茜莎,等.陆英不同工艺提取物对四氯化碳致小鼠肝损伤的影响实验研究[J],《中药材》2008年8期)。专利CN103041238B公开了一种治疗痛风的中药制剂及其制备方法,由以下重量份数的原料药组成:接骨草50~70份、百合片20~40份、怀山药30~60份、墨旱莲10~20份、菝葜20~40份、麦冬30~60份、虎杖10~20份、活血丹20~40份,本发明中药制剂通过凉血卫营、酸碱平衡、调理肝脾肾机能等途径,不仅达到降低尿酸、消肿止痛的效果,还可以恢复原有的自主排酸功能,重建代谢机制,从根本上治愈痛风。专利申请CN107693701A公开了一种治疗痛风性关节炎的药物组合物及其制备方法,包括如下重量份数的原料药:陆英15-20份、附子6-9份、石斛8-16份、泽泻14-16份、枸杞9-14份、元胡12-18份、葛花6-12份、制草乌10-18份、别嘌呤3-8份和秋水仙碱6-10份。本发明的药物组合物对痛风性关节炎有很好的疗效,能够快速减轻症状,对预防痛风复发有很好的作用。本发明的药物组合物由中药和西药复合制成,毒副作用小,对患者的损伤小,治愈后不易复发,适合广大痛风性关节炎患者长期服用。在以上两个专利(申请)文件中提到可以将接骨草在治疗痛风的中药制剂中应用,但是在文件中都没有详细介绍接骨草在其药物中起到何种作用,并且没有对得到的中药制剂进行治病机制分析,很难确定接骨草单独使用是是否具有抗痛风活性。因此,目前还没有对接骨草是否具有调节尿酸、治疗高尿酸血症/痛风活性的相关研究,而且目前关于接骨草的药效和用途研究较少,所以,如何将接骨草扩大化使用,使之产生最大的功效,发挥出应有的效能,仍是医学医药研究的主攻方向。
发明内容
本发明的目的是提供一种治疗痛风的接骨草提取物及其制备方法,本发明的接骨草提取物制备方法简单,成本低,得到的接骨草提取物在制备治疗/预防痛风及其相关疾病或具有调节尿酸功能药物方面应用药物疗效好,成药经济效益高。
为实现上述目的,本发明采用如下技术方案:
一种治疗痛风的接骨草提取物,接骨草提取物的制备方法步骤如下:
(1)取接骨草粉碎成细粉,加入适量水加热提取2~4次,收集提取液浓缩至1.0~1.2g/mL;
(2)采用硅胶色谱柱对以上浓缩液进行柱层析分离,以体积浓度为0~95%的乙醇为流动相进行梯度洗脱,收集体积浓度为30~75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物。
以上步骤(1)具体的提取方法为:
(1)取接骨草粉碎成细粉,加入6~8倍质量蒸馏水先浸泡40~80min,然后加热至80~-100℃提取40~80min,过滤,收集滤液;
(2)滤渣再加入6~8倍质量蒸馏水加热至80~100℃提取40~80min,过滤,收集滤液;
(3)重复提取滤渣1~3次,合并多次提取得到的滤液浓缩至1.0~1.2g/mL,即得接骨草的水提物。
优选地,所述乙醇的体积浓度为0%、30%、60%、75%、95%,收集体积浓度为30%、60%、75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物。
优选地,所述乙醇的体积浓度为0%、15%、30%、45%、60%、75%、90%,收集体积浓度为30%、45%、60%、75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物。
优选地,所述乙醇的体积浓度为15%、35%、55%、75%、95%,收集体积浓度为35%、55%、75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物。
以上接骨草提取物选择性添加常规辅料,按照常规工艺制成临床可接受的用于治疗/预防痛风及其相关疾病或具有调节尿酸功能的药物制剂。
所述制剂包括片剂、胶囊剂、滴丸、颗粒剂等。
所述的常规辅料包括淀粉、乳糖、微晶纤维素、糊精、磷酸钙、聚乙二醇-4000、聚乙二醇-6000、羧甲基纤维素钠、羟丙纤维素或交联聚维酮等中一种以上。
本发明的有益效果是:
1、在本发明中,将接骨草先经过多次重复水提后合并提取液,得到接骨草水提物,利用活性成分的水溶性将接骨草中的活性成分提取出来,避免原料药材入药存在的药效低、副作用大的问题,经过多次对药渣进行重复提取,可以将药材中尽可能多的活性成分提取出来,提高药材的利用率。再对接骨草水提物用不同浓度的乙醇进行洗脱得到不同的洗脱部位,最后收集体积浓度为30~75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物;通过不同浓度的乙醇进行洗脱,可以将接骨草水提物中不同极性部位分开,方便选取得到药用活性最强的部位用于疾病的治疗,扩大药材的应用范围;同时也可以将活性较低或者几乎没有活性的部分分离开来,得到药效更强的提取物。采用本发明的制备方法可以提取得到对痛风及其相关疾病具有显著疗效的接骨草提取物活性部位,极大程度提高了最终得到的接骨草提取物及其药物制剂调节尿酸的活性。接骨草资源丰富,来源方便易得,可用于接骨草提取物的大量制备,而且整个提取制备方法简单易行、成本低、污染小,利于节能减排条件下的大规模生产,产业化前景好。
2、本发明首次发现接骨草提取物具有明显的调节尿酸活性,具有制备预防或治疗痛风及其相关疾病的药物制剂的成药潜力,为开发抗痛风创新药物提供了新的物质基础,具有潜在且巨大的社会效益和经济效益。本发明分别通过研究接骨草提取物对次黄嘌呤引起高尿酸血症小鼠血清尿酸水平的影响以及接骨草提取物对尿酸钠诱导的大鼠足趾肿胀的影响,有力证明了本发明的接骨草提取物对高尿酸血症具有明显的调节尿酸活性。本发明的接骨草提取物还具有祛风利湿、活血散瘀、消炎止痛、镇痉消肿的功效,能用于肝炎、骨折、镇痛等,可以在用于预防或治疗痛风的同时起到治疗其他合并症的效果。另外将接骨草提取物与辅料混合制成片剂、胶囊剂、滴丸、颗粒剂等,这些制剂较为方便服用,能单独或者搭配其他药剂服用,通过内服能将药性通过血液快速输送至病症部位进行有效治疗。
具体实施方式
为了更加详细的介绍本发明,下面结合实施例,对本发明做进一步说明。
实施例1 接骨草水提物的制备
将接骨草粉碎成细粉,取接骨草细粉1kg,加入6L蒸馏水浸泡60min,然后加热至80℃提取60min,过滤,收集滤液;滤渣再加入6L蒸馏水加热至80℃提取60min,过滤,收集滤液;滤渣再加入6L蒸馏水加热至80℃提取60min,过滤,收集滤液;合并3次提取液,浓缩至1.0~1.2g/mL,即得。
实施例2 接骨草水提物的制备
将接骨草粉碎成细粉,取接骨草细粉1kg,加入7L蒸馏水浸泡60min,然后加热至90℃提取60min,过滤,收集滤液;滤渣再加入7L蒸馏水加热至90℃提取60min,过滤,收集滤液;滤渣再加入7L蒸馏水加热至90℃提取60min,过滤,收集滤液;合并3次提取液,浓缩至1.0~1.2g/mL,即得。
实施例3 接骨草水提物的制备
将接骨草粉碎成细粉,取接骨草细粉1kg,加入8L蒸馏水浸泡60min,然后加热至98℃提取60min,过滤,收集滤液;滤渣再加入8L蒸馏水加热至98℃提取60min,过滤,收集滤液;滤渣再加入8L蒸馏水加热至98℃提取60min,过滤,收集滤液;合并3次提取液,浓缩至1.0~1.2g/mL,即得。
实施例4 接骨草水提物的制备
将接骨草粉碎成细粉,取接骨草细粉1kg,加入8L蒸馏水浸泡80min,然后加热至80℃提取80min,过滤,收集滤液;滤渣再加入7L蒸馏水加热至90℃提取60min,过滤,收集滤液;滤渣再加入6L蒸馏水加热至98℃提取40min,过滤,收集滤液;合并3次提取液,浓缩至1.0~1.2g/mL,即得。
实施例5 接骨草水提物乙醇洗脱部位的制备
取采用实施例2的制备方法制备得到的接骨草水提物浓缩液,采用硅胶色谱柱进行柱层析分离,以体积浓度为0%、5%、10%、15%、20%、25%、30%、35%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%的乙醇为流动相依次进行梯度洗脱,分别收集各洗脱物浓缩至浸膏。
其中,由体积浓度为30%、35%、40%、45%、50%、55%、60%、65%、70%、75%的乙醇洗脱得到的洗脱物浸膏用于制备治疗/预防痛风及其相关疾病药物或具有调节尿酸功能药物,药物的药效相对于其他体积浓度乙醇洗脱得到的洗脱物浸膏更佳。
实施例6 接骨草水提物乙醇洗脱部位的制备
取采用实施例2的制备方法制备得到的接骨草水提物浓缩液,采用硅胶色谱柱进行柱层析分离,以体积浓度为0%、15%、30%、45%、60%、75%、90%的乙醇为流动相依次进行梯度洗脱,分别收集各洗脱物浓缩至浸膏。
其中,由体积浓度为30%、45%、60%、75%的乙醇洗脱得到的洗脱物浸膏用于制备治疗/预防痛风及其相关疾病药物或具有调节尿酸功能药物,药物的药效相对于其他体积浓度乙醇洗脱得到的洗脱物浸膏更佳。
实施例7 接骨草水提物乙醇洗脱部位的制备
取采用实施例2的制备方法制备得到的接骨草水提物浓缩液,采用硅胶色谱柱进行柱层析分离,以体积浓度为0%、30%、60%、75%、95%的乙醇为流动相依次进行梯度洗脱,分别收集各洗脱物浓缩至浸膏。
其中,由体积浓度为30%、60%、75%的乙醇洗脱得到的洗脱物浸膏用于制备治疗/预防痛风及其相关疾病药物或具有调节尿酸功能药物,药物的药效相对于由体积浓度为0%、95%的乙醇洗脱得到的洗脱物浸膏的药效更高。
实施例8 接骨草水提物乙醇洗脱部位的制备
取采用实施例2的制备方法制备得到的接骨草水提物浓缩液,采用硅胶色谱柱进行柱层析分离,以体积浓度为15%、35%、55%、75%、95%的乙醇为流动相依次进行梯度洗脱,分别收集各洗脱物浓缩至浸膏。
其中,由体积浓度为35%、55%、75%的乙醇洗脱得到的洗脱物浸膏用于制备治疗/预防痛风及其相关疾病药物或具有调节尿酸功能药物,药物的药效相对于由体积浓度为15%、95%的乙醇洗脱得到的洗脱物浸膏的药效更高。
实施例9 接骨草醇提物的制备
将接骨草粉碎成细粉,取接骨草细粉1kg,加入6L体积浓度为60%的乙醇浸泡60min,然后加热回流提取60min,过滤,收集滤液;滤渣再加入6L体积浓度为60%的乙醇加热回流提取60min,过滤,收集滤液;滤渣再加入6L体积浓度为60%的乙醇加热回流提取60min,过滤,收集滤液;合并3次提取液,浓缩回收乙醇成膏,即得。
实施例10 接骨草提取物片剂的制备
【处方】由实施例7的方法制得的接骨草水提物的60%乙醇洗脱部位(取相当于接骨草药材3.5kg的量)、干淀粉600g;
【制备方法】将接骨草水提物的60%乙醇洗脱部位、干淀粉混匀,加入适量羧甲基纤维素钠、滑石粉,制成颗粒,干燥,压制成1000片,所得的接骨草提取物片,每片含接骨草3.5g。
以上所述的干淀粉、羧甲基纤维素钠和滑石粉均可在市场上购买得到。
实施例11 接骨草提取物胶囊的制备
【处方】由实施例7的方法制得的接骨草水提物的60%乙醇洗脱部位(取相当于接骨草药材3.5kg的量)、干淀粉600g;
【制备方法】将接骨草水提物的60%乙醇洗脱部位、干淀粉混匀,加入适量羧甲基纤维素钠、滑石粉,制成颗粒,干燥,装囊成1000粒,所得的接骨草提取物胶囊,每粒含接骨草3.5g。
以上所述的干淀粉、羧甲基纤维素钠和滑石粉均可在市场上购买得到。
实施例12 接骨草提取物颗粒剂的制备
【处方】由实施例7的方法制得的接骨草水提物的60%乙醇洗脱部位(取相当于接骨草药材10kg的量)、干淀粉1kg;
【制备方法】将接骨草水提物的60%乙醇洗脱部位、干淀粉混匀,加入适量羧甲基纤维素钠、滑石粉,制成颗粒,干燥,分装成1000袋,所得的接骨草提取物颗粒,每袋含接骨草10g。
以上所述的干淀粉、羧甲基纤维素钠和滑石粉均可在市场上购买得到。
药性试验
为了验证本发明接骨草提取物调节尿酸、治疗痛风的高活性,本申请人进行了以下试验:
1、接骨草提取物对次黄嘌呤引起高尿酸血症小鼠血清尿酸水平的影响
供试品:所述接骨草水提物均是由实施例2中所述方法制得的接骨草水提物,所述接骨草醇提物均是由实施例9中所述方法制得的接骨草醇提物,所述接骨草提取物均是由实施例7中所述方法制得的接骨草水提物的60%乙醇洗脱部位。
处理方法:小鼠120只,随机分为12组,每组10只,即正常组,模型组,阳性对照组(别嘌呤醇20mg.kg-1),接骨草提取物高、中、低剂量组(分别相当于接骨草药材12g.kg-1、6g.kg-1和3g.kg-1),接骨草水提物高、中、低剂量组(分别相当于接骨草药材24g.kg-1、12g.kg-1和6g.kg-1),接骨草醇提物高、中、低剂量组(分别相当于接骨草药材24g.kg-1、12g.kg-1和6g.kg-1),灌胃给药,每天1次,正常组和模型组灌胃给予等体积蒸馏水,连续12d。末次给药1 h后,除正常组外,其他各组灌胃给予次黄嘌呤0.4g.kg-1,2.5h后于各组小鼠眼球取血,3000r.min-1离心10min,取血清,采用磷钨酸比色法测定血清尿酸含量。
结果:如表1 所示,与模型组相比较,接骨草提取物高、中剂量组以及接骨草水提物高剂量组、接骨草醇提物高剂量组小鼠的血清尿酸水平明显降低,比较有统计学意义(P<0.05)。
2、接骨草提取物对尿酸钠诱导的大鼠足趾肿胀的影响
供试品:所述接骨草水提物均是由实施例2中所述方法制得的接骨草水提物,所述接骨草醇提物均是由实施例9中所述方法制得的接骨草醇提物,所述接骨草提取物均是由实施例7中所述方法制得的接骨草水提物的60%乙醇洗脱部位。
处理方法:大鼠90只,随机分为9组,每组10只,即正常组,模型组,阳性对照组(秋水仙碱0.5mg.kg-1),接骨草提取物高、低剂量组(分别相当于接骨草药材10g.kg-1和2.5g.kg-1),接骨草水提物高、低剂量组(分别相当于接骨草药材200g.kg-1和10g.kg-1),接骨草醇提物高、低剂量组(分别相当于接骨草药材20g.kg-1和10g.kg-1),灌胃给药,每天1次,正常组和模型组灌胃给予等体积蒸馏水,连续12d。末次给药1h后,正常组于大鼠右后足跖皮下注射0.15mL生理盐水,其他各组于大鼠右后足跖皮下注射0.15mL尿酸钠(100g.L-1)致炎,分别于注射前后测定大鼠右后足跖周径。观察和测定注射后2、4、6、7h大鼠右后足跖的肿胀情况及其周径,计算其肿胀率。
足跖肿胀率=100*(t时间周径-t0时间周径)/t0时间周径。
结果:如表2 所示,与对照组比较,模型组大鼠足趾肿胀率显著增高;和模型组比较,接骨草提取物高剂量组(剂量为10g药材)大鼠在造模后4、6h的肿胀率显著降低,接骨草提取物低剂量组(剂量为2.5g药材)大鼠在造模后4h的肿胀率显著降低;接骨草水提物高剂量组(剂量为20g药材)大鼠在造模后4h的肿胀率显著降低,接骨草醇提物高剂量组(剂量为20g药材)大鼠在造模后4h的肿胀率显著降低,差异有统计学意义(P<0.05)。接骨草水提物低剂量组(剂量为10g药材)和接骨草醇提物低剂量组(剂量为10g药材)无显著影响。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (7)
1.一种治疗痛风的接骨草提取物,所述接骨草为忍冬科接骨木属接骨草的全草,其特征在于,所述接骨草提取物的制备方法步骤如下:
(1)取接骨草粉碎成细粉,加入适量水加热提取2~4次,收集提取液浓缩至1.0~1.2g/mL;
(2)采用硅胶色谱柱对以上浓缩液进行柱层析分离,以体积浓度为0~95%的乙醇为流动相进行梯度洗脱,收集体积浓度为30~75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物。
2.根据权利要求1所述的治疗痛风的接骨草提取物,其特征在于,步骤(1)具体的提取方法为:
(1)取接骨草粉碎成细粉,加入6~8倍质量蒸馏水先浸泡40~80min,然后加热至80~100℃提取40~80min,过滤,收集滤液;
(2)滤渣再加入6~8倍质量蒸馏水加热至80~100℃提取40~80min,过滤,收集滤液;
(3)重复提取滤渣1~3次,合并多次提取得到的滤液浓缩至1.0~1.2g/mL,即得接骨草的水提物。
3.根据权利要求1所述的治疗痛风的接骨草提取物,其特征在于,乙醇的体积浓度为0%、30%、60%、75%、95%,收集体积浓度为30%、60%、75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物。
4.根据权利要求1所述的治疗痛风的接骨草提取物,其特征在于,乙醇的体积浓度为0%、15%、30%、45%、60%、75%、90%,收集体积浓度为30%、45%、60%、75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物。
5.根据权利要求1所述的治疗痛风的接骨草提取物,其特征在于,乙醇的体积浓度为15%、35%、55%、75%、95%,收集体积浓度为35%、55%、75%的乙醇洗脱物浓缩至浸膏即得接骨草提取物。
6.根据权利要求1、3-5任意一项所述的治疗痛风的接骨草提取物,其特征在于,接骨草提取物选择性添加常规辅料,按照常规工艺制成临床可接受的用于治疗/预防痛风及其相关疾病或具有调节尿酸功能的药物制剂。
7.根据权利要求6所述的治疗痛风的接骨草提取物,其特征在于,所述药物制剂包括片剂、胶囊剂、滴丸或颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011452388.0A CN112546085A (zh) | 2020-12-11 | 2020-12-11 | 一种治疗痛风的接骨草提取物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011452388.0A CN112546085A (zh) | 2020-12-11 | 2020-12-11 | 一种治疗痛风的接骨草提取物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112546085A true CN112546085A (zh) | 2021-03-26 |
Family
ID=75061780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011452388.0A Withdrawn CN112546085A (zh) | 2020-12-11 | 2020-12-11 | 一种治疗痛风的接骨草提取物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112546085A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113143902A (zh) * | 2021-03-30 | 2021-07-23 | 深圳湾实验室 | 没食子酸和/或绿原酸治疗冠状病毒感染的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1709416A (zh) * | 2005-06-16 | 2005-12-21 | 江西汇仁药业有限公司 | 陆英提取物及其制备方法 |
-
2020
- 2020-12-11 CN CN202011452388.0A patent/CN112546085A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1709416A (zh) * | 2005-06-16 | 2005-12-21 | 江西汇仁药业有限公司 | 陆英提取物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
陈芳等主编: "《名医别录彩色药图》", 28 February 2017, 贵州科技出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113143902A (zh) * | 2021-03-30 | 2021-07-23 | 深圳湾实验室 | 没食子酸和/或绿原酸治疗冠状病毒感染的用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113521232B (zh) | 一种含有白术的中药组合物 | |
CN101961364A (zh) | 菊苣或菊芋有效部位及其制剂 | |
CN105012452A (zh) | 黄皮叶的新用途 | |
CN105434648A (zh) | 一种治疗急性乳腺炎的中药组合物及其制备方法 | |
CN101569739B (zh) | 一种治疗胆囊炎的中药组合物及其制备方法 | |
CN101214288B (zh) | 一种治疗肝病的中药组合物及其制备方法 | |
CN102475830A (zh) | 一种治疗冠心病心绞痛的药物组合物与其制备方法及制剂 | |
CN106421673A (zh) | 一种治疗hpv病毒感染的中药组合物及其制备方法 | |
CN101347605B (zh) | 一种用于治疗痛风的中药组合物及其制备方法和用途 | |
CN112546085A (zh) | 一种治疗痛风的接骨草提取物及其制备方法 | |
CN101926869B (zh) | 一种治疗头晕、头痛的药物及其制备方法 | |
CN101890063B (zh) | 一种中药降血糖药及其制备方法 | |
CN101390970B (zh) | 一种治疗乙肝的中药及其制备方法 | |
CN103006781B (zh) | 一种具有保肝作用的傣药复合提取物及其制备方法 | |
CN112089738A (zh) | 一种香青藤提取物的制备方法和用途 | |
CN100431566C (zh) | 一种中药组合物及其制备方法和应用 | |
CN108210651B (zh) | 一种用于治疗糖尿病肾病的天然药物组合物及其制备方法 | |
CN101269123A (zh) | 消渴降糖胶囊二次开发的新工艺 | |
CN101229327B (zh) | 治疗慢性乙肝的药物及其制备方法 | |
CN1899574A (zh) | 一种防治肝癌的中药组合物及其应用 | |
CN115025143B (zh) | 一种毛果鱼藤提取物的制备方法和用途 | |
CN104306784A (zh) | 一种用于治疗风湿性关节炎的中药组合物及其制备方法和应用 | |
CN118286310B (zh) | 蕤仁或其提取物、组合物在治疗和/或预防肝损伤中的应用 | |
CN110742983B (zh) | 一种用于治疗痛风急性发作的中药制剂及其制备方法 | |
CN109172756B (zh) | 一种治疗肝病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210326 |
|
WW01 | Invention patent application withdrawn after publication |